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Background: Vaccines may have non-specific effects, affecting resistance to
heterologous pathogens. Veterinary vaccines have seldom been investigated for their
non-specific effects. However, recent observational studies suggest that an inactivated
paratuberculosis vaccine reduced all-cause mortality in goats and cattle.
Aim: We tested if vaccination with a killed mycobacterial vaccine may have heterologous
effects in swine (Sus domesticus), specifically on the pathogenic and clinical effects of a
heterologous challenge with Actinobacillus pleuropneumoniae in young pigs.
Methods: Newborn piglets were randomized to vaccination s.c. with the inactivated
paratuberculosis vaccine Gudair (Zoetis Inc.) (n = 17) or no vaccine (n = 16). At
4–5 weeks after vaccination, all piglets were challenged intra-nasally with a high
(Gudair: n = 8; control: n = 8) or a low (Gudair: n = 9; control: n = 8) dose of the
gram-negative bacterium A. pleuropneumoniae causing acute porcine pleuropneumonia.
The effect and severity of pathogen challenge was evaluated by measuring acute phase
proteins C-reactive protein, haptoglobin and Porcine α1-acid glycoprotein, and by gross
pathology 1 day post challenge. Specific and non-specific in vitro cytokine responses to
vaccination were evaluated in whole blood before bacterial challenge.
Results: The vaccine was immunogenic in the pigs as evidenced by increased IFN-γ
responses to purified protein derivative of Mycobacterium paratuberculosis. However,
Gudair vaccine did not affect IL-6 responses. The gross pathology of the lungs as well
as the acute phase protein responses after the high A. pleuropneumoniae dose challenge
was slightly increased in the vaccinated animals compared with controls, whereas this
was not seen in the animals receiving the low-dose bacterial challenge.
Conclusion: The inactivated paratuberculosis vaccine exacerbated the pathological
and inflammatory effects of an experimental A. pleuropneumoniae infection in young pigs.
Keywords: non-specific effects of vaccines, heterologous immunity, paratuberculosis vaccine, actinobacillus
pleuropneumoniae, pigs (sus domesticus), mycobacterial vaccine
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INTRODUCTION
Observational studies and randomized controlled trials in
humans have shown that many childhood vaccines can
affect resistance to other infections than the targeted disease;
a phenomenon called non-specific effects of vaccines or
heterologous immunity (1). The non-specific effects may be
beneficial, thereby decreasing susceptibility to other infections,
or they may be detrimental, i.e., increasing susceptibility to
other diseases. Common human vaccines with beneficial non-
specific effects include the live vaccines bacillus Calmette-
Guérin (BCG) against tuberculosis (2), measles vaccine (3)
and oral polio vaccine (4). In contrast, non-live vaccines like
the inactivated diphtheria-pertussis-tetanus vaccine may have
negative non-specific effects (5). These non-specific effects of
vaccines, beneficial as well as negative, have generally been most
pronounced in females (3, 5).
The biological mechanisms behind the non-specific effects
of vaccines are not known, and may comprise different
immunological mechanisms, depending on the vaccine in
question. For BCG, one potential mechanism is trained innate
immunity, in which the innate immune system acquires an
enhanced ability to respond to heterologous innate stimulation,
mediated by epigenetic reprogramming of monocytes (6).
Although the evidence from epidemiological and immunological
studies in humans has been corroborated by experimental
animal models, particularly in mice (7), very few studies have
investigated potential non-specific effects of veterinary vaccines,
despite the fact that veterinary vaccines are administered
routinely in virtually all commercial animal production systems
to an increasing number of animals. If veterinary vaccines have
non-specific effects, there may be potential to optimize the
current use of vaccines to production animals, thereby reducing
mortality and morbidity, antibiotics use and the implicated
financial losses.
Recently, it was reported that goats allocated to the
commercial heat-inactivated oil-in-water emulsified Gudair
vaccination (Zoetis Inc.) against Mycobacterium avium subsp.
paratuberculosis infection had a significant reduction in all-
cause culling compared to non-vaccinated peers, regardless of
age. Pathological examinations of the culled corpses detected
lesions consistent with paratuberculosis infection only in adults,
indicating that Gudair vaccine conferred protection against non-
paratuberculosis infection (8). A similar non-specific beneficial
effect has also recently been reported in cattle for which the
bovine version of killed paratuberculosis vaccine (Silirum, Zoetis
Inc.) given before age 3 months was associated with a reduction
in all-cause culling to an extent, which seemingly exceeded the
specific protection against paratuberculosis, as indicated by post-
mortem examination of slaughtered cows in similar herds (9).
Gudair vaccine contains inactivated heat-killed whole M.
avium subsp. paratuberculosis of the M. tuberculosis complex,
which also includesM. tuberculosis andM. bovis BCG. Beneficial
non-specific effects of heat-killed M. tuberculosis in the oil-
emulsified formulation known as Freund’s complete adjuvant
(FCA) were demonstrated several decades ago. E.g., mice pre-
treated with FCA had markedly reduced viremia following
inoculation with Foot-and-mouth disease virus (10). Recently, a
commercial veterinary vaccine containing cell wall components
from M. phlei in oil-emulsion was reported to decrease all-cause
morbidity in feedlot cattle (11), and to improve survival after
Enterotoxigenic Escherichia coli induced diarrhea in neonatal
cattle (12). Early murine experimental studies of non-specific
effects also found that heat-killed BCG or M. fortuitum
administered s.c. or i.p. improved survival after subsequent
Staphylococcus aureus infection alone (13) or S. aureus mixed
with endotoxin (14), and crude cell wall extract from M. phlei
administered i.p. or i.v. improved survival after subsequent
infections with S. aureus or Salmonella enteritidis (15). The
mortality reducing effect of heat-killed BCG persisted from 13
days through 10 weeks after immunization (13).
Although the above studies using paratuberculosis
vaccine did take the vaccine-specific protection against
paratuberculosis into account, it would be desirable to
reproduce these data in paratuberculosis-free settings.
Previously, paratuberculosis vaccination of goats (16) and
cattle (17) was shown to reduce gross pathology and bacterial
colonization after experimental exposure to M. caprae and M.
bovis, respectively, more than 3 months after immunization.
This heterologous protection offered by M. paratuberculosis
vaccination to other mycobacterial infections could be due to
cross-reactive T-cell mediated adaptive immunity or innate
training-like mechanisms.
As paratuberculosis is not endemic to slaughter pigs, no such
vaccine is licensed to use in pigs. This may reduce the risk of
adaptive cross-reactive mechanisms playing any significant role
in the study, making the pig a relevant model to investigate
if the non-specific protection is mediated by innate immune
mechanisms in addition to the relatively high physiological
similarity between pigs and humans (18).
We aimed to investigate if vaccination of piglets with
the inactivated paratuberculosis vaccine Gudair may non-
specifically influence the pathology and inflammation following
a subsequent challenge with the Gram-negative, facultative
anaerobic coccobacillus Actinobacillus pleuropneumoniae
causing acute porcine pleuropneumonia.
MATERIALS AND METHODS
Three weeks prior to farrowing, three pregnant sows (Danish
Landrace/Danish Yorkshire crossbreeds) were immunized sub-
cutaneously behind the left ear base with 1ml Gudair (heat-
inactivated M. avium subsp. paratuberculosis F316 strain, lot #
160209, CZ Veterinaria).
Randomization
Within 2 days after farrowing, the three litters of piglets (Danish
Landrace/Danish Yorkshire crossbreeds, paternal lineage Duroc,
n = 33) were allocated by litter alternatingly to receiving either
Gudair vaccine (n = 17, 0.5ml, s.c. in the right shoulder) or
nothing (n = 16, control group) (Figure 1). The piglets were
tailed docked, but males were not castrated.
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FIGURE 1 | Timeline of experiment.
Follow-Up Post-randomization
After weaning, the piglets were transferred to the experimental
facilities at the Technical University of Denmark, and placed
in two boxes with a balanced distribution of vaccination
treatment, sex, weight and litter, and to intranasal challenge
with A. pleuropneumoniae scheduled on day 36 or 41 after
vaccination, respectively.
Challenge
A seed lot of A. pleuropneumoniae Danish field strain 4226,
serotype 2 (19) stored at −80◦C was cultured overnight at 37◦C
onmodified pleuropneumonia-like organism (PPLO)-agar plates
using E. coli as a nurse strain, suspended in 0.9% NaCl, and
adjusted to desired concentration by turbidity. Pigs were lightly
anesthetized with (Zolazepam/Tiletamine) and inoculated by
spraying the bacterial solution with a manual nebulizer (LMA
Mad Nasal, Teleflex) directly into the nostrils.
Low-Dose Challenge
At 36 days after vaccination, pigs in the low-dose group received
1.5 × 108 CFU A. pleuropneumoniae/animal administered by
1ml in either nostril.
High-Dose Challenge
At 41 days after vaccination, pigs in the high-dose group received
1 × 109 CFU A. pleuropneumoniae/animal administered by 1ml
in either nostril.
Concentration and purity of the inoculation suspensions were
verified by seeding on PPLO and blood agar plates, respectively.
Follow-up Post-challenge
Within 24 h of A. pleuropneumoniae inoculation, animals were
sedated by Zoletil (Zolazepam/Tiletamine) and sacrificed by
captive bolt pistol and bleeding.
Necropsy was performed for characterization of gross
lesions. The injection site was examined and lung lesions
were scored semi-quantitatively in regard to severity
modified after Baarsch et al. (20); 0 = no lesions, 1 =
hemorrhage, non-consolidated processes; 2 = small localized
A. pleuropneumoniae-like lesions; 3 = large, extensive AP-like
lesions. A. pleuropneumoniae-like lesions were defined as
areas with hemorrhage, lung consolidation and necrosis (red
hepatization), and fibrin exudation.
For re-isolation of the inoculation strain from lung (Lobus
cranialis dexter), liver (Lobus hepatis sinister lateralis) and spleen
a scalpel was inserted into the tissue and struck on PPLO agar
and cultured at 37◦C; the following day, emerging colonies were
enumerated and categorically rated as 0, 1–10, 11–50, 51–100, or
>100 colonies.
Weight and rectal temperatures were evaluated before and
after challenge.
Blood Samples
On day 33 after vaccination (before challenge), heparinized
blood was collected from the jugular vein, distributed as 1
ml/well in 24-well flat bottom plates (Costar) for overnight
(23 h) incubation in humidified 37◦C, 5% CO2 atmosphere with
the following stimulation panel (final concentrations in cultures
are indicated):
Purified protein derivative of Johne’s disease (PPDj, 10
ug/ml, Promise strain, DTU National Veterinary Institute),
lipopolysaccharide from E.coli (LPS, 10 ng/ml, Sigma),
Pam3CSK4 (1 ug/ml, Invitrogen), PHA-L (2 ug/ml, Sigma)
or medium alone. Supernatants were harvested and stored at
−20◦C until quantification by monoclonal sandwich ELISAs of
IL-6 (Porcine IL-6 DuoSet ELISA, R&D Systems) or IFN-γ (21).
Acute Phase Protein ELISAs
C-reactive protein (CRP), haptoglobin and porcine α1-acid
glycoprotein (PAGP) were analyzed from serum samples
collected on day 0 and day 1 of A. pleuropneumoniae inoculation
using in-house ELISA protocols (22–24).
Statistics
Data was analyzed in StataMP ver. 12 (StataCorp, US) or
GraphPad Prism ver6 (GraphPad Software) using Kruskal-Wallis
test for IFN-γ, IL-6, CRP, haptoglobin, weight, temperature
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TABLE 1 | Background information.
Gudair Control
N 17 16
Sex male/female 8/9 11/5
Weight kg day0, median (min-max) 1.5 (1.1–2.0) 1.5 (1.1–2.4)
Weight kg day33, median (min-max) 8.0 (3.5–10.0) 8.3 (3.0–11.0)
App low dose / high dose 9/8 8/8
App, Actinobacillus pleuropneumoniae.
and colony count data in unpaired analysis and using
Wilcoxonmatched-pairs signed-rank test for paired analyses. For
haptoglobin, IL-6 and IFN-γ, a few observations were above or
below the assay range and were assigned the value of the highest
or lowest, respectively, reliably quantified value of the standard
curve in the statistical analysis. Pig α1-acid glycoprotein (PAGP)
levels were analyzed as relative values to the index defined by the
mean level of the low A. pleuropneumoniae dose control animals
before challenge. Pathology scores were dichotomized as ≥2 vs.
<2 and analyzed using Wilcoxon rank-sum test.
Ethics
The animal experiments were approved by the Danish Animal
Experiment Inspectorate, approval number 2015-15-0201-00520.
RESULTS
The piglets in the paratuberculosis vaccine and control groups
were similar with respect to weight on the day of treatment
allocation. There was no difference in the weight gain by
vaccination status (Table 1).
The paratuberculosis vaccinated sows showed no severe
reaction after paratuberculosis vaccination. All paratuberculosis
vaccinated piglets had a local reaction at the injection site,
although the severity was variable, ranging from a diffuse
cutaneous reaction with slight pus exudation to ulceration of the
epidermis (Supplementary Figure 1).
In vitro IFN-γ responses to PPDj were increased 33 days
after paratuberculosis vaccination compared to the control
group (Figure 2). There was no evidence of paratuberculosis
vaccination inducing a differential IFN-γ response to themitogen
PHA or of a differential IL-6 response to PPDj or PHA, or to the
innate TLR stimulants LPS (TLR4) or Pam3CSK4 (TLR2/1).
In the low A. pleuropneumoniae dose group, no behavioral
changes could be observed during the 24 h following inoculation.
In the high-dose group, several animals had an increased
respiratory rate. On average, the rectal temperature slightly
decreased following the low-dose challenge, particularly in the
control group and only modestly so in the paratuberculosis
vaccinated, whereas the temperature increased after the
high-dose challenge irrespective of vaccination status,
with no difference between paratuberculosis-vaccinated
and control pigs 1 day after challenge (Figure 3). The
weight change from day of challenge to the day after
challenge was minor and not significant at any rate,
although the miniscule trends corroborated the other
clinical observations: Weight gain was smaller in animals
receiving the high A. pleuropneumoniae dose vs. the low
A. pleuropneumoniae dose. The weight gain was slightly
negative in Gudair-vaccinated animals receiving the high A.
pleuropneumoniae dose, but slightly positive in control animals
(data not shown).
In the low A. pleuropneumoniae dose group, there were only
minor lung lesions, and 9/17 had no lesions; there were no
evident association between vaccination status and pathology
score (Table 2). The high A. pleuropneumoniae dose induced
lung lesions in all animals, and extensive reactions in 12/16
animals (pathology score 3) presenting with acute interstitial
edema, acute lung necrosis (red hepatization) with fibrinogen
exudation and fibrinous pleuritis. Of paratuberculosis vaccinated
animals 8/8 had a pathology score of ≥2, whereas 5/8 in the
control group scored≥2 (p= 0.06). Overall, the pathology scores
and the colony counts were positively correlated; 11/12 animals
receiving the high-dose App with a pathology score of 3 also had
a CFU >100.
After the low-dose challenge, A. pleuropneumoniae could not
be isolated from lung tissues in any of the paratuberculosis
vaccinated animals (0/9), but in 3/8 of the control animals
(p= 0.05); in contrast, after the high A. pleuropneumoniae dose,
bacteria were isolated in 8/8 paratuberculosis vaccinated, and
in 5/8 control animals (p = 0.19) (Table 2). No bacteria were
isolated from the liver, but A. pleuropneumoniae was isolated
from the spleen in 1/8 paratuberculosis vaccinated (colony count
of >100) and 1/8 control animal (colony count 51-100) after the
high inoculation dose (data not shown).
With the very limited number of observations, there was
no indication of a sex-differential effect of paratuberculosis
vaccination on pathology score or bacterial burden of
the lung tissues after the low A. pleuropneumoniae dose.
After the high A. pleuropneumoniae dose, there was non-
significant indication of an increase in pathology score
and colony counts after paratuberculosis vaccination in
females, with 4/4 paratuberculosis vaccinated female pigs
having a pathology score of 3 contrasting only 1/3 control
female pigs with a pathology score of 3 and 2/3 with a
score of 0. No differences in distribution of pathology
scores were observed in males across vaccination status
(Supplementary Table 1).
Before challenge, in pigs allocated for the high-dose challenge
the serum levels of the positive acute phase proteins CRP
and haptoglobin were slightly but non-significantly lower in
paratuberculosis vaccinated pigs compared with control pigs,
while the serum level of the negative acute phase protein PAGP
was slightly higher (Figure 4). Other than that, there were no
observed differences by vaccination status before challenge.
CRP and haptoglobin were increased after both low-
dose and high-dose challenges in both paratuberculosis
vaccinated and control pigs. The largest increase was seen
in paratuberculosis vaccinated pigs receiving the high A.
pleuropneumoniae dose. A similar inverse pattern was
observed for the negative acute phase protein PAGP. For
pigs challenged with the high A. pleuropneumoniae dose, this
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FIGURE 2 | In vitro cytokine responses. Concentrations of cytokines of IFN-γ (A,B) and IL-6 (C–F) in whole blood cultures after overnight stimulation with
purified protein derivative of M. avium subsp. paratuberculosis (A,C), phytohaemagglutinin (B,D), lipopolysaccharide (E) or Pam3CSK4 (F), including the
non-stimulated medium alone (Nil), comparing Gudair vaccinated (n = 17) with non-vaccinated control animals (n = 16). Statistical test for difference by vaccination
using Kruskal-Wallis and for paired analysis of stimulation effect using Wilcoxon matched-pairs signed-rank test; *p < 0.05; **p < 0.01; ***p < 0.001. Note the
different scales in the sub-graphs. Means of the subgroups are indicated on the graphs.
resulted in a significantly higher post-challenge haptoglobin
level in paratuberculosis-vaccinated compared with control
pigs (Figure 4).
Stratified by sex, although the sex-differential was not large
or statistically significant in its own right, the effect of the
paratuberculosis vaccine Gudair on the fold change of all acute
phase proteins from before to after inoculation was larger in
females compared with males, in line with the pattern observed
for the pathology scores in the high A. pleuropneumoniae dose
recipients (Supplementary Figure 2).
DISCUSSION
We found indication that Gudair vaccination exacerbated the
pathology and systemic inflammatory response after inoculation
with a high dose of A. pleuropneumoniae in young pigs, although
a cautious interpretation is warranted due to the relatively
small number of animals involved. In contrast, there was
slight indication of an ameliorating effect of Gudair in animals
receiving a low A. pleuropneumoniae dose challenge. There was
no difference in leukocyte cytokine responses to polyclonal ex
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FIGURE 3 | Rectal temperatures before and after challenge. Rectal temperatures immediately before challenge and the following day, comparing previously
Gudair-vaccinated with control animals receiving a low dose (Gudair: n = 9; control: n = 8) or a high dose (Gudair: n = 8; control: n = 8) of A. pleuropneumoniae
(App). Statistical analysis of change in temperatures after challenge using Wilcoxon matched-pairs signed-ranks test; *p < 0.05.
vivo stimulation in pigs vaccinated with Gudair compared with
non-vaccinated controls.
The previously reported beneficial non-specific effects of
Gudair have been suggested to be mediated via mechanisms
of trained immunity (8, 9), as is indicated for BCG (6).
The mycobacterium cell wall harbors several immunogenic
constituents including muramyl dipeptide (MDP), the smallest
peptidoglycan component of the mycobacterial cell wall and
a ligand specific to NOD2, a cytoplasmic receptor of the
innate immune system. MDP activation of NOD2 has been
demonstrated to induce trained immunity of monocytes (6).
MDP administration in mice prior to or immediately after a
lethal challenge withKlebsiella pneumoniae reduced themortality
(25). Also a wide array of glycoconjugates interacts with the
host immune system, including trehalose dimycolate (TDM), also
known as mycobacterial cord factor, the major lipid in the outer
membrane of mycobacteria. Pre-treatment with mycobacterially
derived TDM has also been shown to improve survival of mice
challenged with K. pneumoniae or Listeria monocytogenes (26).
Whereas, the animal studies discussed above find beneficial
effects of inactivated mycobacterial vaccine formulations, some
studies in humans find, however, that inactivation of vaccines
abrogates the beneficial effects. A study in human adults found
that inactivation of BCG may compromise the innate training
effect. Compared with the live BCG, immunization with gamma-
irradiated BCG induced only minimal effect on monocyte
responses ex vivo to innate stimulation, albeit a significant
increase in heterologous ex vivo immune (Th1/Th17) responses
was found (27). Moreover, in an experimental sepsis study in
human volunteers, immunization with gamma-irradiated BCG 5
days prior to i.v. administration of LPS did not ameliorate the
endotoxemia-induced immunoparesis, measured as a decrease in
ex vivo cytokine responses (28).
One explanation of this differential effect of live vs.
killed BCG may be the shorter persistence of BCG in the
killed formulation, and therefore a reduced exposure in time,
immunological compartment space or dose of the innate
training stimulants. An additional explanation may be that
inactivation abrogates microbial RNA production and thereby
greatly diminish the stimulation of the TLR8 pathway, which is
important for monocyte activation and subsequent establishment
of immunity including induction of T follicular helper cell
differentiation, plasma cell maturation and humoral responses to
vaccination (29).
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TABLE 2 | Colony counts and pathology scores.
n Colony counts Pathology score
0 1–10 11–50 51–100 >100 0 1 2 3
App high dose, ∼1 × 109 CFU/animal (McFarland 5)
Gudair 9 9 0 0 0 0 4 5 0 0
control 8 5 0 1 0 2 5 1 2 0
p = 0.05 p = 0.12
App low dose, ∼1 × 108 CFU/animal (McFarland 0.5)
Gudair 8 0 0 0 1 7 0 0 1 7
control 8 3 0 0 0 5 0 3 0 5
p = 0.19 p = 0.06
Colony counts after re-cultivation of lung tissues and pathological assessment of inner
organs after challenge with A. pleuropneumoniae (App), comparing Gudair vaccinated
with unvaccinated control animals. Statistical analysis using Kruskal-Wallis test for colony
counts and Wilcoxon rank-sum test for pathology scores dichotomized as ≥2 vs. <2.
In fact, the prevailing evidence from human clinical data and
epidemiological studies find that beneficial non-specific effects
are generally limited to live vaccines (30), including BCG (2),
live attenuated measles vaccine (3, 31), oral polio vaccine (4) and
smallpox vaccine (32); in contrast, inactivated human vaccines
such as diphtheria-tetanus-pertussis vaccine have been associated
with detrimental effects, particularly in girls (5). This dichotomy
of live vs. inactivated vaccines was recently corroborated in an
analysis of a large multicenter trial of a new malaria vaccine
candidate, the non-live RTS,S vaccine (33). Here, despite a
modest specific protection against malaria disease, the malaria
vaccine was associated with a markedly higher mortality in
females (34).
Observational studies in humans have indicated that the
immunity transferred from the mother to the infant may
enhance the beneficial non-specific effects of the BCG vaccine
(35, 36) and the measles vaccine (37), presumably due to an
interaction between the specific antibodies and the vaccine
antigen in the recipient (38). Therefore, in order to take
advantage of this potential enhancing effect of maternally derived
immunity, all three sows received Gudair vaccine 3 weeks prior
to farrowing. Whether the maternal immunization interacted
with the vaccination of the offspring could not be elucidated
under the present study design in which all offspring was born
to immunized mothers. This hypothesis would be interesting
to investigate in future studies. An interesting immunological
feature in pigs is that in addition to uptake of maternally-derived
antibodies, maternal leukocytes from the colostrum may also
cross the intestinal barrier and enter lymphatic organs (39, 40).
To our knowledge there is no prior experience with the Gudair
vaccine in swine, and the vaccine has not been tested in other
animals in early life. We did not perform initial vaccine dose-
optimisation studies in the piglets, but decided to apply half the
standard dose recommended to goats and sheep above 6 weeks
of age. The vaccine was immunogenic as evidenced by increased
vaccine-specific interferon recall responses after vaccination, as
well as reactogenic as evidenced by swollen regional lymph nodes,
palpable nodules, and a few ulcers at the injection site.
In contrast to the few existing studies on non-mycobacterial
effects of the mycobacterial veterinary vaccines, the present study
was conducted in a vaccine-targeted pathogen-free setting, as the
indoor-housed Danish industry pigs can safely be assumed to be
free from paratuberculosis exposure.
The challenge organism used here is in the Gram-negative,
facultative anaerobic coccobacillus A. pleuropneumoniae of the
Pasteurellaceae family, which is a highly contagious pathogen
endemic to modern farm pigs. Most commercially available
vaccines against A. pleuropnemoniae are made from whole-cell
inactivated bacteria and confer only partial and often serotype-
specific protection (41). The A. pleuropneumoniae infection
is associated with a local and systemic upregulation of pro-
inflammatory cytokines and acute-phase proteins, in addition to
widespread necrotic reactions in the airways directly mediated
by the haemolytic and cytotoxic effects of bacterial LPS and Apx
toxins or indirectly as a result of the provoked inflammatory host
responses following the A. pleuropneumoniae induced damages
(42). Whether mycobacterial vaccination non-specifically can
enhance defense mechanisms against such endotoxin-mediated
inflammation remains to be verified. As discussed above,
there was no ameliorating effect of immunization with
inactivated BCG 5 days prior to induction of experimental
endotoxemia in human volunteers (28), nor were there any
large effects of BCG vaccination on LPS in vitro stimulated
cytokine responses in infants from Guinea-Bissau (43) or the
UK (44).
Various non-adaptive defense mechanisms have been
found of importance in clearance and/or amelioration of
the immunological pathogenesis in A. pleuropneumoniae
infections, including an effective mucociliary clearance
mechanism which promote a rapid elimination of A.
pleuropneumoniae (45); the ability of the host to exert
micronutrient restriction of particularly iron; rapid recruitment
of neutrophils and macrophages; effective opsonisation
and killing of A. pleuropneumoniae by neutrophils and
macrophages; complement-mediated bacteriolysis; tolerance
to or neutralization of the potent bacterial toxins [reviewed
in (42)]. Whether one or more of these mechanisms may be
non-specifically enhanced by vaccination strategies, and in
particular affected by precedent Gudair vaccination, remains
to be investigated; the present study does not indicate a
protective effect by a killed mycobacterial vaccine against
heterologous infection.
Two different inoculation doses of A. pleuropneumoniae
were applied. Prior experiments in our laboratory using
the same strain of A. pleuropnemoniae (unpublished data)
produced very little clinical and pathological effects; we
therefore decided to split the infectious challenge in two
parts separated by sufficient time to allow the evaluation and
potential adjustment of optimal dose for the second half of
the animals.
Whereas, the low dose gave only minor macroscopic
necrotic lesions, the high dose produced severe acute lesions
in all animals. This differential treatment obviously reduced
the statistical power of our analysis, but in turn may have
indicated an interesting differential effect of the immune
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FIGURE 4 | Acut-phase proteins before and after challenge. Means of
concentrations of acute phase proteins C-reactive protein (CRP), haptoglobin
and the negative acute phase protein pig α1-acid glycoprotein (PAGP) in
serum immediately before challenge (day 0) and the following day (day 1),
comparing previously Gudair-vaccinated with control animals; the animals
were receiving a low dose (Gudair: n = 9; control: n = 8) or a high dose
(Gudair: n = 8; control: n = 8) of A. pleuropneumoniae (App) on day 0. PAGP
levels are relative to the index defined by the mean level of the low A.
pleuropneumoniae control animals before challenge. Note the different scales
in the sub-graphs. Statistical analysis of change in concentrations from day 0
to day 1 using Wilcoxon matched-pairs signed-rank test (for paired samples)
and analysis of differences by Gudair vaccination on day 0 concentrations and
on fold changes after challenge using Kruskal-Wallis test; *p < 0.05; **p <
0.01. Error bar is standard deviation. Hatched horizontal line on Haptoglobin
graph is the lower limit of detection.
activation on the subsequent challenge, with indication of
an exacerbating effect of paratuberculosis vaccination in a
high inoculation dose, contrasting the effect in the low
inoculation dose.
In contrast to most of the murine challenge studies discussed
above using survival as end-point and observing the animals over
several days to weeks, we evaluated clinical, pathological and
immunological end-points on sacrifice 24 h after challenge for
animal welfare reasons due to the significant suffering imposed
by the A. pleuropneumoniae infection.
The mode of administration of the inoculum bypassed
the mucosa-associated lymphoid tissue barriers of the upper
respiratory tract as the suspension of 2ml bacteria was sprayed
directly into the nostrils of the anesthetized animals and passively
or actively inhaled to colonize the lower respiratory airways.
In addition, it was noted that the left lungs were consistently
much more affected, as the sedated animals when returned to the
pen after inoculation were laid to rest on the left flank. Hence,
the inoculum had a somewhat focused non-natural distribution
in the lungs.
Whereas, this may not fully mimic a natural way of
exposure, leaving the possibility that immune checkpoints of the
upper respiratory tract potentially affected by vaccination
have been bypassed, the fact that A. pleuropneumoniae
under natural conditions may be vectored on aerosol
particles passing directly into the lower respiratory tract,
where the bacteria preferentially bind to epithelial cells
(46), renders the administration model relevant to evaluate
the local defense property of the lower airways. Of note, a
parenteral mode of i.v. or i.p. administration has typically
been applied in the above discussed experimental septic
murine models.
None of the experimental evidence of mycobacterial non-
specific beneficial effects discussed above arises from studies in
pigs. Although the pig is increasingly used as an experimental
model organism, there are certain fundamental differences
between the porcine and the murine or the human physiology,
such as the higher body temperature of the pig, the inverted
lymph nodes, higher gamma-delta T cell numbers in circulation,
and differences in the epitheliochorial placentation prohibiting
transplacental transfer of immunoglobulins (18, 47). Whether
these or other biological differences may play an important
role in non-specific immunity needs further investigation.
Studies of BCG in human babies find that BCG has beneficial
non-specific effects on mortality when given immediately after
birth. Piglets were vaccinated within 2 days of life, at which
stage the immune responses and functions are clearly dampened
compared to later in life, but far from completely abrogated
(48–50); one study found that an inactivated single-dose
immunization against Mycoplasma hyopneumoniae of 4–5
day-old piglets significantly enhanced resistance to subsequent
M. hyopneumoniae challenge (51). Herein, the increased specific
adaptive in vitro IFN-γ responses in immunized pigs confirm
the immunological competence of the young piglets to respond
to vaccination.
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CONCLUSION
The inactivated Gudair vaccine against paratuberculosis
marketed for use in ruminants did not protect young pigs against
a subsequent heterologous challenge with a highly pathological
dose of A. pleuropneumoniae, and in contrast may have had
negative effects.
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C-reactive protein (CRP), haptoglobin and the negative acute phase protein pig
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or a high dose. PAGP levels are relative to the index defined by the mean level of
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